A urine culture returns an ESBL-producing Escherichia coli, and the reflex is a carbapenem. In a substantial proportion of these patients that is unnecessary, and in a setting with rising carbapenem resistance it is actively harmful.
The distinction that matters is cystitis versus pyelonephritis or bacteraemia. For uncomplicated lower urinary tract infection, the drug only has to reach high concentrations in urine, and several agents do that while being useless systemically. Nitrofurantoin and fosfomycin both retain activity against most ESBL producers and both concentrate in urine — which is exactly why neither is appropriate for pyelonephritis or any infection above the bladder. An aminoglycoside, given as a short course with renal monitoring, is the other carbapenem-sparing option and does work for upper tract disease.
The practical sequence: confirm the site clinically before choosing, check the reported susceptibilities rather than assuming resistance from the ESBL label, and reserve the carbapenem for pyelonephritis, sepsis, or failure of a narrower agent. Then de-escalate as soon as the culture allows — a carbapenem started empirically and never reviewed is the commonest way a stewardship policy fails.
One caution worth repeating: nitrofurantoin needs adequate renal function to reach urinary concentrations, so it is the wrong choice in the older patient with reduced clearance who is also the one most likely to be carrying an ESBL.
- Establish the site first — nitrofurantoin and fosfomycin are for cystitis only, never for pyelonephritis or bacteraemia
- Read the actual susceptibility report; ESBL does not automatically mean resistance to every oral agent
- Consider a short aminoglycoside course with renal monitoring where the upper tract is involved
- Avoid nitrofurantoin where renal clearance is reduced — it will not reach urinary concentrations
- Set a review date on every empirical carbapenem; the failure is usually not starting it, it is never stopping it
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for infectious diseases, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free